Search clinical trials for: AMG 199

Total 4981 results

Amgen

Not yet recruiting

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen

Active, not recruiting

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Obesity | Overweight | Type 2 Diabetes Mellitus

United States, Czechia, Taiwan, Canada, Japan, Korea, Republic of, Germany, Hungary, Australia, Hong Kong, Spain, Poland
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Renal Impairment

United States
Amgen

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Cardiovascular Disease

United States, Australia
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Chronic Migraine or Episodic Migraine

United States, Germany, Austria, Czechia, Canada, Denmark, Finland, Sweden
Kyowa Kirin Co., Ltd.

Completed

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Japan
Jonsson Comprehensive Cancer Center
NantCell, Inc.

No longer available

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Ewing Sarcoma
Amgen

Completed

AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Asthma
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Terminated

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Migraine

United States
Amgen

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, United Kingdom
Amgen

Completed

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Migraine

United States
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Kyowa Kirin Co., Ltd.

Completed

Safety Study of AMG 531 in Japanese Subjects With ITP

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Terminated

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Schizophrenia

United States
Alexza Pharmaceuticals, Inc.

Completed

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Cyclic Vomiting Syndrome

United States
Amgen

Completed

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Obesity

United States
Amgen

Terminated

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Obesity

United States
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Chronic Graft-versus-host Disease (cGVHD)

United States
Amgen

Completed

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 529 First in Human Study

Cardiovascular

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...

Completed

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Amgen

Completed

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

End Stage Renal Disease | Chronic Kidney Disease | Kidney Disease | Hyperphosphatemic
Amgen

Completed

Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Asthma
Amgen

Completed

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Osteopenia
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

China
Kerry Rogers
Janssen Research & Development, LLC

Withdrawn

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Chronic Lymphocytic Leukemia | Loss of Chromosome 17p
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, United Kingdom
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Amgen

Completed

Phase II Study to Evaluate the Efficacy of AMG 317

Asthma
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Amgen

Completed

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Obesity

United States
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Elevated Serum Lipoprotein(a)

Hong Kong
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Hepatic Impairment

United States
Amgen

Terminated

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia, Germany
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

Chronic Graft-versus-Host Disease (cGVHD)

Australia
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

United States
Amgen

Terminated

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Amgen

Completed

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581 (FIH)

Schizophrenia or Schizoaffective Disorder

United States
Amgen

Terminated

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Schizophrenia

United States, Canada, Spain, Australia, New Zealand, Russian Federation, Singapore
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Inflammatory Disease

New Zealand
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Amgen

Terminated

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Schizophrenia

United States, France, United Kingdom, Malaysia, Poland, Czech Republic

3

Subscribe